58 related articles for article (PubMed ID: 26663400)
1. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.
Pardanani A; Lasho T; Barraco D; Patnaik M; Elala Y; Tefferi A
Am J Hematol; 2016 Mar; 91(3):E10-1. PubMed ID: 26663400
[No Abstract] [Full Text] [Related]
2. A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement.
Coltro G; Santi R
Blood; 2023 May; 141(20):2541. PubMed ID: 37200055
[No Abstract] [Full Text] [Related]
3. Osteolytic lesion as initial presentation in FIP1L1-PDGFRA-rearranged myeloid/lymphoid neoplasm with eosinophilia: a case report.
Lv Y; Yao X; Ling Q; Suo S; Wang J; Zhao S; Gao X; Tong H; Jin J; Zhang X; Yu W
Ann Hematol; 2024 Jan; 103(1):357-360. PubMed ID: 37777636
[No Abstract] [Full Text] [Related]
4. The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders.
Cross NCP; Godfrey AL; Cargo C; Garg M; Mead AJ;
Br J Haematol; 2021 Nov; 195(3):338-351. PubMed ID: 34409596
[No Abstract] [Full Text] [Related]
5. False-Negative Testing for FIP1L1::PDGFRA by Fluorescence in situ Hybridization Is a Frequent Cause of Diagnostic Delay.
Pongdee T; Berry A; Wetzler L; Sun X; Thumm L; Yoon P; Kuang FL; Makiya M; Constantine G; Khoury P; Rheinbay E; Lane AA; Maric I; Klion AD
Acta Haematol; 2023; 146(4):316-321. PubMed ID: 37285821
[TBL] [Abstract][Full Text] [Related]
6. Drug sensitivity profiling identifies potential therapies for myeloid neoplasm with eosinophilia driven by a novel G3BP1-PDGFRB fusion gene.
Wang J; Xu L; Li Y; Wang J; Shao Y; Lai W; Yong J; Zhao L; Wei X; Gao C; Liu D; Gao X; Zhang Y
Leuk Lymphoma; 2024 Apr; 65(4):521-525. PubMed ID: 38157478
[No Abstract] [Full Text] [Related]
7. Novel
Alsouqi A; Kleinberger J; Werner TS; Awan R; Chopra S; Rea B; Aggarwal N; Yatsenko SA; Farah R; Bailey NG
Haematologica; 2023 Nov; 108(11):3181-3185. PubMed ID: 37102594
[No Abstract] [Full Text] [Related]
8. Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: A workshop report with focus on novel entities and a literature review including paediatric cases.
Saft L; Kvasnicka HM; Boudova L; Gianelli U; Lazzi S; Rozman M
Histopathology; 2023 Dec; 83(6):829-849. PubMed ID: 37551450
[TBL] [Abstract][Full Text] [Related]
9. Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of
Zhang L; Zhu X; Qu W; Lu Y; Feng Z; Zhao L
Haematologica; 2023 Dec; 108(12):3506-3510. PubMed ID: 37102606
[No Abstract] [Full Text] [Related]
10. [Bone destruction was the initial symptom in myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRα: a case report].
Guo Y; Lyu GQ; Zhang Y; Wang LH; Wu JR; Lu XL; Qin WL; Wu S
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):195. PubMed ID: 38604798
[No Abstract] [Full Text] [Related]
11.
Yin CC; Tam W; Walker SM; Kaur A; Ouseph MM; Xie W; K Weinberg O; Li P; Zuo Z; Routbort MJ; Chen S; Medeiros LJ; George TI; Orazi A; Arber DA; Bagg A; Hasserjian RP; Wang SA
Haematologica; 2023 Nov; ():. PubMed ID: 37981812
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
[TBL] [Abstract][Full Text] [Related]
13. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
Patnaik MM; Tefferi A
Am J Hematol; 2024 Jun; 99(6):1142-1165. PubMed ID: 38450850
[TBL] [Abstract][Full Text] [Related]
14. Genomics of PDGFR-rearranged hypereosinophilic syndrome.
Rheinbay E; Qi M; Bouyssou JM; Oler AJ; Thumm L; Makiya M; Maric I; Klion AD; Lane AA
Blood Adv; 2023 Jun; 7(11):2558-2563. PubMed ID: 36652685
[No Abstract] [Full Text] [Related]
15. Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.
González-López O; Muñoz-González JI; Orfao A; Álvarez-Twose I; García-Montero AC
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626091
[TBL] [Abstract][Full Text] [Related]
16. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.
Patnaik MM; Tefferi A
Am J Hematol; 2018 Jun; 93(6):824-840. PubMed ID: 29878489
[TBL] [Abstract][Full Text] [Related]
17. Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of
Baer C; Muehlbacher V; Kern W; Haferlach C; Haferlach T
Haematologica; 2018 Aug; 103(8):e348-e350. PubMed ID: 29567772
[No Abstract] [Full Text] [Related]
18. (A Critical Appraisal of) Classification of Hypereosinophilic Disorders.
Kahn JE; Groh M; Lefèvre G
Front Med (Lausanne); 2017; 4():216. PubMed ID: 29259972
[TBL] [Abstract][Full Text] [Related]
19. A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia.
Oberley MJ; Denton C; Ji J; Hiemenz M; Bhojwani D; Ostrow D; Wu S; Gaynon P; Raca G
Cancer Genet; 2017 Oct; 216-217():91-99. PubMed ID: 29025601
[TBL] [Abstract][Full Text] [Related]
20. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.
Martinelli G; Mancini M; De Benedittis C; Rondoni M; Papayannidis C; Manfrini M; Meggendorfer M; Calogero R; Guadagnuolo V; Fontana MC; Bavaro L; Padella A; Zago E; Pagano L; Zanotti R; Scaffidi L; Specchia G; Albano F; Merante S; Elena C; Savini P; Gangemi D; Tosi P; Ciceri F; Poletti G; Riccioni L; Morigi F; Delledonne M; Haferlach T; Cavo M; Valent P; Soverini S
Leukemia; 2018 Jan; 32(1):139-148. PubMed ID: 28663576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
